Prodotti competitors / Area Liver
PBC competitive landscape updates

Ocaliva
- FDA issued a new safety communication regarding risk of liver injury in non-cirrhotic PBC patients treated with Ocaliva (12/12/24)
- The FDA identified a significant risk among non-cirrhotic PBC patients taking Ocaliva based on data from the Phase 3b/4 COBALT study (747-302)
- This update follows the FDA’s 2021 restrictions on Ocaliva’s use for patients with advanced cirrhosis
- The EU’s General Court reversed its decision to suspend the European Commission’s (EC) revocation of conditional marketing approval for Advanz’s Ocaliva (11/26/24)
- Recall that the EC General Court had temporarily suspended the EC’s revocation to hear Advanz petitions for “interim measures” that would further delay Ocaliva’s removal from the market
- The General Court denied the first of Advanz’s petitions but continues to hear arguments in this case, meaning Ocaliva’s marketing status could change again
- EU patients with active Ocaliva prescriptions can still access treatment in some Countries
Iqirvo
-
- Iqirvo’s Phase 2 ELMWOOD trial investigating Iqirvo in PSC was listed as “fully recruited”; data readout expected in 2026 (PCD: Aug 2026), and potential launch in 2031+, following a Phase 3 trial
- Ipsen discussed its rare disease portfolio as consisting of Iqirvo, Bylvay (odevixibat) and Sohonos (palovarotene)
- Ipsen also reiterated that data readout for the global Phase 3 ELSPIRE trial (N=72; PCD: Oct 2026) of Iqirvo in 2L PBC is expected in 2026 [known]
- France’s High Authority of Health (Haute Autorité de Santé, HAS) denied post-market authorization early access for Ipsen’s Iqirvo for 2L PBC in combination with UDCA, or as monotherapy in patients who do not tolerate UDCA (01/07/25)
- Based on clinical data (Phase 2 GFT505b-216-1 and Phase 3 ELATIVE), the Transparency Committee (CT) concluded that:
- Iqirvo is not an innovation in PBC treatment
- Iqirvo demonstrated weak efficacy on PBC progression and symptoms
- Bezafibrate is a suitable 2L treatment option, minimizing unmet need
- While the HAS did not fully agree with all CT conclusions, it considers bezafibrate to be an adequate 2L PBC treatment option, consistent with the general sentiment in France
- Based on clinical data (Phase 2 GFT505b-216-1 and Phase 3 ELATIVE), the Transparency Committee (CT) concluded that:
- Ipsen listed the new Phase 3 ELONSEN trial (N=18; PCD: Mar 2026) in Japan assessing Iqirvo as 2L treatment for adult PBC patients with inadequate response or intolerance to UDCA (12/11/24)
- The study aims to determine if Iqirvo reduces alkaline phosphatase (ALP) and total bilirubin levels in Japanese patients
- Assuming data readout and filing occurs soon after the study’s primary completion date (Mar 2026) and a ~12-month review period, Iqirvo could potentially be approved in Japan in H1 2027
Pipeline
Linerixibat
- CHMP posted the Jan 2025 meeting agenda (Jan 27th-30th), with GSK’s linerixibat (IBATi) listed under Section 8 “Pre-submission issues” (01/27/25)
- The committee will discuss GSK’s request for accelerated assessment of linerixibat for cholestatic pruritus in PBC
- Assuming filing acceptance in early 2025 (in line with prior GSK guidance), estimated approval could occur in ~Q3 2025 if the CHMP agrees to an accelerated assessment
- Notably, GSK does not include linerixibat in its list of 5 key 2025 launches discussed during the 2025 J.P. Morgan Healthcare Conference (01/14), suggesting the company could expect linerixibat revenues to be low compared to other approvals anticipated in 2025
Grazie per il tuo feedback!